A UNIQUE THERAPY 4 YOUR PATIENTS

STELARA® has a unique mechanism of action as the only available biologic that selectively targets IL-23 and IL-12 cytokines

ONLY 4 MAINTENANCE DOSES PER YEAR after 2 starter doses1*

*Every 12 weeks after 2 starter doses at Weeks 0 and 4.

View the
SAFETY PROFILE
for STELARA®

Resources 4 your practice and your patients

Reference: 1. STELARA [package insert]. Horsham, PA: Janssen Biotech, Inc; 2016.